Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
More study recommended for AI and ovarian suppression in premenopausal women
October 20th, 2005
Researchers recommend additional study for aromatase inhibitors and ovarian suppression in premenopausal women. According to investigators in the United States, "In postmenopausal women with advanced breast cancer, numerous phase III trials have been performed comparing the third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole and the steroidal AI (S-AI) exemestane in the 'first-line' setting against tamoxifen and in the 'second-line' setting against megestrol acetate. In both settings, the AIs were at least as efficacious or superior in some endpoints with a preferable toxicity profile including a lower incidence of thrombotic...
Source: Women's Health Weekly (2005-10-20)
|
